Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change. In the 2022 version: JAKi now separate sentence following bDMARDs, with proviso to mention risk. Sometimes guidelines have to tell us what we’ve all inevitably been expecting #EULAR2022 @RheumNow https://t.co/RPbPNi3vcW

#highlight n•1 💫 The presence of specific peripheral blood T cell sub-populations associated w/ disease flares in RA pts in remission after cs or bioDMARDs tapering or cessation identified in 2 different abstracts OP0011 and OP0074 @RheumNow #EULAR2022 https://t.co/SO2AgtkyTP

Stimakovits et al. Influence of placebo vs active comparator in RA clinical trials. ACR response rates systematically higher in studies with active comparators. ACR20 OR 1.64 (1.44-1.86), ACR50 OR 1.46 (1.28-1.71), ACR70 OR 1.61 (1.28-2.02) @RheumNow #EULAR2022 POS0563 https://t.co/x7PQH11oue

We’re in the #EULAR2022 highlights: basic/translational first. Wait, don’t go… because Temra cells are cool. Up in RA pts who are TNFi-IR, & may actually be more than a bystander. Understanding TNFi resistance is path to: predicting it knowing best what to do with it @RheumNow https://t.co/22Y6iinSbH

Redondo-Rodriguez et al. Abatacept in RA-ILD. Prospective study 38 patients. 73.6% improved/stablised with abatacept at median 17 month follow-up @RheumNow #EULAR2022 POS0654 https://t.co/D2du0hAXIy

#POS1207 #EULAR2022 In N=98 RA patients with poor antibody response to rituximab after two doses, 19% responded after 3rd dose. Associated with longer Time of vaccine from last RTX & interestingly ultra dose 200mg used in the Netherlands @RheumNow https://t.co/TTXXtOU6vp

Talking about tapering studies in inflammatory arthritis, but true throughout all of rheumatology: Not all flares are equal. This area is full of nuance, we need to think more closely about how we study them. #EULAR2022 @RheumNow https://t.co/tzqqNZv5Ct

Everything's better with MTX Controlled RA on b/tsDMARDs: can we taper MTX? maintaining remission pooled OR 0.81 (0.68-0.97) Unless I'm reading it wrong: it's true many will be fine, but keeping MTX adds benefit (even in short term, before ADAb) POS0286 #EULAR2022 @RheumNow https://t.co/ZlwXHgACWd

Charles-Schoeman et al. ORAL Surveillance, post-hoc analysis of risk factor combinations. 65+ ever smokers appear at particular risk @RheumNow #EULAR2022 POS0674 https://t.co/UyTOITBTX9

If rheumatoid arthritis comes and goes before a rheumatologist lays their hands on it, is it really RA? We're born skeptical on this. Ronald van Vollenhoven poses questions on what it means for studying drug-free remission in established RA disease #EULAR2022 @RheumNow https://t.co/9GJoqYtVBP